Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
289.80
-1.97 (-0.68%)
Aug 18, 2026, 7:38 AM EDT - Market open
Ligand Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 290.54 | 268.09 | 167.13 | 131.31 | 196.25 | 241.54 |
Revenue Growth | 54.89% | 60.40% | 27.28% | -33.09% | -18.75% | 47.68% |
Gross Profit Gross Profit Growth | 235.92 | 172.36 | 134.63 | 96.27 | 107.34 | 147.26 |
Operating Income Operating Income Growth | 100.1 | 47.2 | 23.02 | 9.82 | 3.04 | 66.25 |
Net Income Net Income Growth | 197.22 | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 |
Earnings Per Share EPS Growth | 9.19 | 6.13 | -0.22 | 2.94 | -1.98 | 3.32 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue from Intangible Royalty Assets Revenue from Intangible Royalty Assets Growth | 151.16 | 132.53 | 95.33 | 83.91 | 72.53 | 48.93 |
Income from Financial Royalty Assets Income from Financial Royalty Assets Growth | 36.95 | 28.47 | 13.44 | 1.05 | 0.39 | - |
Captisol Captisol Growth | 35.1 | 40.21 | 30.88 | 28.37 | 104.5 | 164.25 |
Contract Revenue and Income Contract Revenue and Income Growth | 67.34 | 66.87 | 27.48 | 17.98 | 18.84 | - |
Revenue (Total) Revenue (Total) Growth | 290.54 | 268.09 | 167.13 | 131.31 | 196.25 | 241.54 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,358 | 733.52 | 256.17 | 170.31 | 211.87 | 341.11 |
Total Debt Total Debt Growth | 1,131 | 451.54 | 7.15 | 6.18 | 87.75 | 324.44 |
Net Cash (Debt) Net Cash Growth | 226.31 | 281.98 | 249.01 | 164.13 | 124.12 | 16.66 |
Net Cash Growth | -5.42% | 13.24% | 51.72% | 32.23% | 644.83% | - |
Net Cash Per Share Net Cash Per Share Growth | 10.56 | 13.89 | 13.61 | 9.24 | 7.36 | 0.97 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 131.71 | 49.36 | 97.05 | 49.58 | 137.85 | 78.8 |
Capital Expenditures CapEx Growth | -0.28 | -0.45 | -1.82 | -3.52 | -12.35 | -8.76 |
Free Cash Flow Free Cash Flow Growth | 131.44 | 48.91 | 95.23 | 46.06 | 125.5 | 70.04 |
Free Cash Flow Growth | 145.13% | -48.64% | 106.76% | -63.30% | 79.19% | 39.72% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 81.20% | 64.29% | 80.55% | 73.31% | 54.70% | 60.97% |
Operating Margin | 34.45% | 17.61% | 13.77% | 7.48% | 1.55% | 27.43% |
Pretax Margin | 81.90% | 59.29% | 1.51% | 48.48% | 18.35% | 29.89% |
Profit Margin | 67.88% | 46.42% | -2.41% | 39.72% | -17.00% | 23.66% |
FCF Margin | 45.24% | 18.24% | 56.98% | 35.07% | 63.95% | 29.00% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 31.74 | 29.90 | - | 23.88 | - | 45.18 |
Forward PE | 42.33 | 35.20 | 53.58 | 35.07 | 298.37 | 298.37 |
P/FCF Ratio | 44.25 | 76.09 | 21.26 | 27.04 | 8.99 | 36.86 |
PS Ratio | 20.02 | 13.88 | 12.11 | 9.48 | 5.75 | 10.69 |